enGene

Performance

About enGene

enGene is a biotechnology company focused on mainstreaming non-viral genetic medicines, developing detalimogene for non-muscle invasive bladder cancer (NMIBC). The company emphasizes delivering non-viral gene therapy directly to mucosal tissues to reduce treatment burden and improve patient outcomes, with clinical development including the LEGEND program and RMAT/Fast Track designations from the FDA. Headquartered in the United States, enGene highlights its DDX platform and a patient-centered approach to advancing genetic medicines for urological cancers and beyond.